# A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

> clinical trial · VERIFIED · 2026-08-10

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Carcinoma, Non-Small-Cell Lung

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06623422

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.